Advanced

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Hagman, Helga LU ; Frödin, Jan-Erik; Berglund, Åke; Sundberg, Jan; Vestermark, Lene; Albertsson, Maria; Fernebro, Eva LU and Johnsson, Anders LU (2016) In Annals of Oncology 27(1). p.140-147
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Oncology
volume
27
issue
1
pages
140 - 147
publisher
Oxford University Press
external identifiers
  • scopus:84960127748
ISSN
1569-8041
DOI
10.1093/annonc/mdv490
language
English
LU publication?
no
id
ec3e1c14-a029-4ba0-8444-6f6421ef4074
date added to LUP
2017-04-12 16:18:10
date last changed
2017-11-14 09:50:21
@article{ec3e1c14-a029-4ba0-8444-6f6421ef4074,
  author       = {Hagman, Helga and Frödin, Jan-Erik and Berglund, Åke and Sundberg, Jan and Vestermark, Lene and Albertsson, Maria and Fernebro, Eva and Johnsson, Anders},
  issn         = {1569-8041},
  language     = {eng},
  number       = {1},
  pages        = {140--147},
  publisher    = {Oxford University Press},
  series       = {Annals of Oncology},
  title        = {A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial},
  url          = {http://dx.doi.org/10.1093/annonc/mdv490},
  volume       = {27},
  year         = {2016},
}